Today: 30 June 2026
Opendoor stock today: OPEN edges up in premarket as traders watch jobless claims, rates
31 December 2025
2 mins read

Opendoor stock today: OPEN edges up in premarket as traders watch jobless claims, rates

NEW YORK, December 31, 2025, 07:19 ET — Premarket

  • Opendoor shares were up about 0.1% in premarket trading, holding near Tuesday’s close.
  • Traders are bracing for the weekly U.S. jobless-claims report due after the opening bell approaches.
  • The stock has stayed volatile amid meme-trading attention and elevated short interest.

Opendoor Technologies Inc (OPEN) shares ticked higher in premarket trading on Wednesday, up about 0.1% at $5.84. The stock finished Tuesday up 0.2%, after trading between $5.64 and $5.86 on volume of about 42 million shares.

The stock heads into the final trading day of 2025 with liquidity thin and rate-sensitive names prone to outsized swings. Weekly U.S. jobless claims are due at 8:30 a.m. ET — released a day early because Thursday is a federal holiday — and U.S. markets are shut on Thursday for New Year’s Day.

Rate expectations remain the main tape for housing-linked stocks after the Federal Reserve’s December meeting minutes, released Tuesday, underscored divisions even after a quarter-point cut to a 3.50%-3.75% target range. Investors have been recalibrating how fast borrowing costs might fall in 2026.

Opendoor runs an “iBuying” business — buying homes directly from sellers and reselling them — while also operating a marketplace that connects home sellers with buyers. The model’s profitability depends heavily on home-price moves, financing costs and how quickly the company can turn inventory. Reuters

The stock has stayed on retail traders’ radar after sharp swings earlier in 2025, with social-media interest often showing up in bursts of volume. Stocktwits again flagged Opendoor as a meme-stock name this week.

Short interest — the portion of shares borrowed and sold by investors betting the stock will fall — can amplify those moves by forcing short sellers to buy back stock in a rally. About 116.6 million Opendoor shares were sold short as of Dec. 15, roughly 15% of the float, MarketBeat data showed.

The company’s most recent strategic move was a push deeper into mortgages through an acquisition disclosed last week. Chief Growth Officer Morgan Brown wrote on X, “We’re going to fix homeownership and that includes mortgage,” announcing Opendoor’s acquisition of HomeBuyer.com and the hiring of Dan Green as director of mortgage growth. TipRanks

Opendoor has also been reshaping its leadership team going into 2026. The company said it appointed Christy Schwartz as chief financial officer effective Jan. 1, 2026, and named Lucas Matheson president.

Opendoor and Offerpad remain among the few scaled U.S. iBuyers after Zillow and Redfin exited their home-flipping operations in prior years. That leaves investors fewer pure-play ways to trade swings in U.S. housing transactions and financing conditions.

For Wednesday’s regular session, traders are likely to take their cues from the jobless-claims print and moves in Treasury yields, which feed directly into mortgage-rate expectations. A push out of Tuesday’s tight range would be the first sign that year-end positioning is giving way to fresh risk appetite.

Looking beyond the holiday break, the next major macro waypoint for rate-sensitive stocks is the Federal Reserve’s Jan. 27-28 policy meeting. Investors will keep parsing labor-market and inflation releases for clues on whether the Fed delivers more cuts after three in 2025.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • SELLAS Life Sciences (NASDAQ:SLS) Drops 7.77% After 8-K Filing Ahead of REGAL Data
    June 30, 2026, 10:28 AM EDT. SELLAS Life Sciences shares dropped 7.77% to $14.25 on Tuesday after an 8-K showing senior management agreements and as the market waits for Phase 3 REGAL data on galinpepimut-S in AML. The study is approaching a milestone with 78 of 80 survival events, making some investors cautious. The stock recently hit a 52-week high of $15.67, but resistance is holding there with support at the 20-day simple moving average around $8.87. Technicals are flashing overbought with the RSI at 85.19, which could mean sharper pullbacks. SELLAS works on cancer therapies including GPS and CDK9 drugs, tying its shares to updates around leadership moves and clinical trials.
Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386
Previous Story

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next
Next Story

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next

Go toTop